Skip to main content

Advertisement

SpringerLink
Log in

Intravesical Therapy for BPS/IC

  • BPS/Interstitial Cystitis (D Castro-Diaz and Y Igawa, Section Editors)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This manuscript gives a recent overview of intravesical treatments in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). The newest data on GAG replenishment therapy, intravesical local anaesthetics, DMSO, botulinum toxin, experimental drugs, and ways of application are discussed.

Recent Findings

The literature data show symptomatic therapeutic successes in a limited number of patients with most treatments discussed here. The heterogeneity of BPS/IC, the absence of clear knowledge of the cause in each patient, the different phenotypes included in the same research sample, the variability of dosage, and application frequency make interpretation of study results difficult. Treatment can aim at restoring a deficient GAG, to block the pain with local analgesics, and to lessen local inflammation, but it is uncertain from which treatment an individual patient will benefit most: trial and error are mostly used. Exclusion of many confusable diseases and Hunner lesions is the first step to indicate the treatment options with the most chance of success.

Summary

The actual trial and error approach is the only available way so far for intravesical treatment in patients with BPS/IC. The overall results are acceptable, but a better understanding of the symptom syndrome and better phenotyping of BPS/IC patients will most probably improve the outcome in individual patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Wyndaele JJJ, Riedl C, Taneja R, Lovász S, Ueda T, Cervigni M. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019;38(2):535–44. https://doi.org/10.1002/nau.23900Gives major GAG data.

    Article  PubMed  Google Scholar 

  2. Towner RA, Smith N, Saunders D, Van Gordon SB, Wisniewski AB, Tyler KR, et al. Contrast-enhanced magnetic resonance imaging as a diagnostic tool to assess bladder permeability and associated colon cross-talk: preclinical studies in a rat model. J Urol. 2015;193(4):1394–400. https://doi.org/10.1016/j.juro.2014.10.120.

    Article  PubMed  Google Scholar 

  3. Towner RA, Wisniewski AB, Wu DH, Van Gordon SB, Smith N, North JC, et al. A feasibility study to determine whether clinical contrast-enhanced magnetic resonance imaging can detect increased bladder permeability in patients with interstitial cystitis. J Urol. 2016;195(3):631–8. https://doi.org/10.1016/j.juro.2015.08.077.

    Article  PubMed  Google Scholar 

  4. • Fall M, Nordling J, Cervigni M, Dinis Oliveira P, Fariello J, Hanno P, et al. Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report. Scand J Urol. 2020;54:91–8. https://doi.org/10.1080/21681805.2020.1730948Underlies difference between classic and nonclassic BPS/IC.

    Article  PubMed  Google Scholar 

  5. Fall M, Nordling J, Cervigni M, Oliveira PD, Fariello J, Hanno P, et al. Comments to Editorial by J. Curtis Nickel. It is premature to categorize Hunner lesion interstitial cystitis as a distinct disease entity. Scand J Urol. 2020;54:355–6. https://doi.org/10.1080/21681805.2020.1784269.

    Article  PubMed  Google Scholar 

  6. Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater. 2015;19:66–75. https://doi.org/10.1016/j.actbio.2015.02.030.

    Article  CAS  PubMed  Google Scholar 

  7. Liu S, Zhang C, Liao P, Lu Y, Luo D. Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials. Int Urogynecol J. 2020. https://doi.org/10.1007/s00192-020-04490-3.

  8. Barua JM, Arance I, Angulo JC, Riedl CR. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2016;27:1137–47. https://doi.org/10.1007/s00192-015-2890-7.

    Article  PubMed  Google Scholar 

  9. Pyo JS, Cho WJ. Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/chondroitin sulfate instillation for interstitial cystitis/painful bladder syndrome. Cell Physiol Biochem. 2016;39:1618–25. https://doi.org/10.1159/000447863.

    Article  CAS  PubMed  Google Scholar 

  10. Gülpınar Ö, Esen B, Kayış A, Gökçe Mİ, Süer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018;37:257–62. https://doi.org/10.1002/nau.23284.

    Article  CAS  PubMed  Google Scholar 

  11. Cervigni M, Sommariva M, Tenaglia R, Porru D, Ostardo E, Giammò A, et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36:1178–86. https://doi.org/10.1002/nau.23091.

    Article  CAS  PubMed  Google Scholar 

  12. Yang JY, Wei W, Lan YL, Liu JQ, Wang HB, Li. Role of bladder hydrodistention and intravesical sodium hyaluronate in the treatment of interstitial cystitis. Urol J. 2015;12:2417–21.

    PubMed  Google Scholar 

  13. Taneja R. (Personal communication). Paper presented at ESSIC, the Annual Meeting of the International Society for the Study of Bladder Pain Syndrome; 2017; Budapest, Hungary.

  14. Kim A, Lim B, Song M, Choo MS. Pretreatment features to influence the effectiveness of intravesical hyaluronic acid instillation in refractory interstitial cystitis/painful bladder syndrome. Int Neurourol J. 2014;18:163–7. https://doi.org/10.5213/inj.2014.18.3.163.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lovász S. Which is the easiest and the optimal way to follow up on our patients? [oral presentation]. Paper presented at ESSIC, the Annual Meeting of the International Society for the Study of Bladder Pain Syndrome; 2017b; Budapest, Hungary.

  16. Lovász S. Intravesical instillation therapy in bladder pain: a challenging new way with remarkable advantages. [Oral presentation]. Paper presented at ESSIC, the Annual Meeting of the International Society for the Study of Bladder Pain Syndrome; 2015; Rome, Italy.

  17. Lovász S. Pain in the urethra [oral presentation]. Paper presented at ESSIC, the Annual Meeting of the International Society for the Study of Bladder Pain Syndrome; 2017a; Budapest, Hungary.

  18. Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, Lee MH, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int J Urol. 2016;23:542–9. https://doi.org/10.1111/iju.13118.

    Article  PubMed  Google Scholar 

  19. Engeler D, Baranowski A, Borovicka J, Cottrell AM, Dinis-Oliveira P, Elneil S et al. EAU guidelines on chronic pelvic pain, Edn. Presented at the EAU Annual Congress London 2017. ISBN 978–90–79754-91-5. 2017. EAU Guidelines Office, Arnhem, The Netherlands. Retrieved 17 May 2017, from https://uroweb.org/guideline/chronic-pelvic-pain/. Accessed 2 Feb 2020.

  20. • Digesu DA, Tailor V, Bhide AA, Khullar V. The role of bladder instillation in the treatment of bladder pain syndrome: is intravesical treatment an effective option for patients with bladder pain as well as LUTS? Int Urogynecol J. 2020;31:1387–92. https://doi.org/10.1007/s00192-020-04303-7Looks into BPS/IC and LUTS.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22:7739–44.

    PubMed  Google Scholar 

  22. Henry RA, Morales A, Cahill CM. Beyond a simple anaesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85:1025–33. https://doi.org/10.1016/j.urology.2015.01.021.

    Article  PubMed  Google Scholar 

  23. Lyer S, Lotsof E, Zhou Y, Tran A, Botros C, Sand P, et al. Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study. Int Urogynecol J. 2017;28:1335–40. https://doi.org/10.1007/s00192-017-3266-y.

    Article  Google Scholar 

  24. Rawls WF, Cox L, Rovner ES. Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: a review. Neurourol Urodyn. 2017;36:1677–84. https://doi.org/10.1002/nau.23204.

    Article  PubMed  Google Scholar 

  25. • Schachar JS, Evans RJ, Parks GE, Zambon J, Badlani G, Walker SJ. Histological evidence supports low anaesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2019;30:1863–70. https://doi.org/10.1007/s00192-019-04038-0Explains low anaesthetic bladder narcose as marker of bladder-centric BPS/IC.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lim YN, Dwyer P, Murray C, Karmakar D, Rosamilia A, Thomas E. Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2017;28(7):1085–9. https://doi.org/10.1007/s00192-016-3232-0.

    Article  PubMed  Google Scholar 

  27. • Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology. 2018;125:1793–802. https://doi.org/10.1016/j.ophtha.2018.04.026First to report ophthalmologic danger of PPS.

    Article  PubMed  Google Scholar 

  28. Ferguson TJ, Geraets RL, Barker MA. Chronic use of pentosan polysulfate sodium associated with risk of vision-threatening disease. Int Urogynecol J. 2019;30:337–8. https://doi.org/10.1007/s00192-018-3850-9.

    Article  PubMed  Google Scholar 

  29. Zhang W, Deng X, Liu C, Wang X. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Int Urogynecol J. 2017;28(4):515–25. https://doi.org/10.1007/s00192-016-3079-4.

    Article  PubMed  Google Scholar 

  30. Gao Y, Liao L. Intravesical injection of botulinum toxin A for treatment of interstitial cystitis/bladder pain syndrome: 10 years of experience at a single centre in China. Int Urogynecol J. 2015;26(7):1021–6. https://doi.org/10.1007/s00192-015-2631-y.

    Article  PubMed  Google Scholar 

  31. Chiu B, Tai HC, Chung SD, Birder LA. Botulinum toxin A for bladder pain syndrome/interstitial cystitis. Toxins. 2016;8(7):201. https://doi.org/10.3390/toxins8070201.

    Article  CAS  PubMed Central  Google Scholar 

  32. Wang JP, Wang Q, Wu QH, Chen Y, Wu P. Intravesical botulinum toxin A injections for bladder pain syndrome/interstitial cystitis: a systematic review and meta-analysis of controlled studies. Med Sci Monit. 2016;22:3257–67. https://doi.org/10.12659/MSM.897350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. • Mishra N, Riedl C, Shah S, Pathak N. Intravesical tacrolimus in treatment of intractable interstitial cystitis/bladder pain syndrome - a pilot study. Int J Urol. 2019;26 Suppl 1:68–72. https://doi.org/10.1111/iju.13978Presents intravesical tacrolimus.

    Article  CAS  PubMed  Google Scholar 

  34. • Jhang JF, Wu SY, Teng-Yi L, Kuo HC. Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case-control pilot study. Low Urin Tract Symptoms. 2019;11:O42–7. https://doi.org/10.1111/luts.12212New research.

    Article  CAS  PubMed  Google Scholar 

  35. Chuang YC, Chermansky C, Kashyap M, Tyagi P. Investigational drugs for bladder pain syndrome (BPS)/interstitial cystitis (IC). Expert Opin Investig Drugs. 2016;25:521–9. https://doi.org/10.1517/13543784.2016.1162290 39.

    Article  CAS  PubMed  Google Scholar 

  36. Hung SY, Chancellor DD, Chancellor MB, Chuang YC. Role of liposome in treatment of overactive bladder and interstitial cystitis. Urol Sci. 2015;26:3–6.

    Article  Google Scholar 

  37. ClinicalTrials.gov. Safety, tolerability and efficacy study of LiRIS® 400 mg in women with interstitial cystitis, ended 2016.

Download references

Author information

Authors and Affiliations

  1. Faculty GGW, University Antwerp, Antwerp, Belgium

    Wyndaele Jean-Jacques

  2. Brasschaat, Belgium

    Wyndaele Jean-Jacques

Authors
  1. Wyndaele Jean-Jacques
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wyndaele Jean-Jacques.

Ethics declarations

Conflict of Interest

The author declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on BPS/Interstitial Cystitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jean-Jacques, W. Intravesical Therapy for BPS/IC. Curr Bladder Dysfunct Rep 16, 6–11 (2021). https://doi.org/10.1007/s11884-020-00625-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-020-00625-w

Keywords

Search

Navigation